U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Google Secures Pentagon AI Deal for Classified Projects 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 17355274. A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
